Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis

被引：181

作者：

Carrasco, Maria Alejandra ^{[1
]}

机构：

[1] Univ Nacl Cuyo, Ctrvis Mendoza, RA-5500 Mendoza, Argentina

来源：

CORNEA | 2008年 / 27卷 / 06期

关键词：

bevacizumab; corneal neovascularization; herpetic keratitis;

D O I：

10.1097/QAI.0b013e31815b833a

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To report an 81-year-old woman with corneal neovascularization secondary to herpetic stromal keratitis treated with subconjunctival bevacizumab and to discuss the role of this novel antiangiogenic treatment. Methods: Case report and review of medical literature. Results: A dramatic regression of corneal vessels was observed 1 week after the injection. After a 3-month follow-up, there was no recurrence of corneal revascularization. Conclusions: Bevacizumab may be a valid complementary treatment in patients with corneal neovascularization caused by herpetic stromal keratitis.

引用

页码：743 / 745

页数：3

共 16 条

[1] Primary intravitreal bevackumab (Avastin) for diabetic macular edema - Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up [J].

Arevalo, J. Fernando ;

Fromow-Guerra, Jans ;

Quiroz-Mercado, Hugo ;

Sanchez, Juan G. ;

Wu, Lihteh ;

Maia, Mauricio ;

Berrocal, Maria H. ;

Solis-Vivancol, Adriana ;

Farah, Michel E. .

OPHTHALMOLOGY, 2007, 114 (04) :743-750

[2]

Azar Dimitri T, 2006, Trans Am Ophthalmol Soc, V104, P264

[3]

BOCK F, GRAEFES ARC IN PRESS

[4] Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis [J].

Bock, Felix ;

Onderka, Jasmine ;

Dietrich, Tina ;

Bachmann, Bjorn ;

Kruse, Friedrich E. ;

Paschke, Matthias ;

Zahn, Grit ;

Cursiefen, Claus .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (06) :2545-2552

[5] Corneal neovascularization [J].

Chang, Jin-Hong ;

Gabison, Eric E. ;

Kato, Takuji ;

Azar, Dimitri T. .

CURRENT OPINION IN OPHTHALMOLOGY, 2001, 12 (04) :242-249

[6] Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival [J].

Cursiefen, C ;

Cao, JT ;

Chen, L ;

Liu, Y ;

Maruyama, K ;

Jackson, D ;

Kruse, FE ;

Wiegand, SJ ;

Dana, MR ;

Streilein, JW .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (08) :2666-2673

[7] VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment [J].

Cursiefen, C ;

Chen, L ;

Borges, LP ;

Jackson, D ;

Cao, JT ;

Radziejewski, C ;

D'Amore, PA ;

Dana, MR ;

Wiegand, SJ ;

Streilein, JW .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (07) :1040-1050

[8] Topical bevacizumab therapy for corneal neovascularization [J].

DeStafeno, John J. ;

Kim, Terry .

ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (06) :834-836

[9] Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration [J].

Emerson, M. Vaughn ;

Lauer, Andreas K. ;

Flaxel, Christina J. ;

Wilson, David J. ;

Francis, Peter J. ;

Stout, J. Timothy ;

Emerson, Geoffrey G. ;

Schlesinger, Thomas K. ;

Nolte, Susan K. ;

Klein, Michael L. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (04) :439-444

[10] Intracameral bevacizumab for iris rubeosis [J].

Grisanti, Salvatore ;

Biester, Sabine ;

Peters, Swaantje ;

Tatar, Olcay ;

Ziemssen, Focke ;

Bartz-Schmidt, Karl Ulrich .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :158-160

← 1 2 →